Stock Price Prediction

Innate Pharma (IPHA) has a bullish outlook with a price target of $11.50, representing a significant upside from its current price of $1.83. Analysts highlight its strong focus on immuno-oncology and promising pipeline, particularly in therapeutic antibodies for cancer treatment. The stock's undervaluation and robust analyst consensus make it an attractive investment opportunity.

IPHA stock currently trades at $1.83, significantly below its analyst consensus price target of $9.33, representing a potential upside of over 450%. However, its negative P/E ratio (-3.71) and clinical-stage status indicate high risk, as the company is not yet profitable. Despite strong buy ratings from analysts, the stock's speculative nature and reliance on clinical trial success make it vulnerable to volatility.